Key facts
- Regenity Biosciences’s last known valuation is $430.0M (Aug 2019).
- Notable investors include Audax Private Debt, Linden (Chicago), Cinven, Acceleration International.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Regenity Biosciences
- ·The full record, as it builds
Funding rounds
No funding rounds for Regenity Biosciences are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Regenity Biosciences
Manufacturer of collagen and mineral-based medical devices that support the body's natural ability to regenerate in areas such as tissue, bone, and nerve repair. The company produces collagen membranes for use in oral surgery, dental implants, bone defects, and ridge augmentation procedures, and also conducts research and development in its laboratory and provides products for neurosurgery and orthopedic purposes, thereby delivering advanced devices and implants that support the body's natural ability to regenerate.
- Sector
- Healthcare
- HQ
- Paramus, NJ, United States
- Founded
- 1997
- Employees
- 250
- Website
- regenity.com/
- Ownership
- Privately Held (backing)
Regenity Biosciences doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Regenity Biosciences shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Regenity Biosciences in its N-PORT filings yet. We sweep new filings monthly.